About 11 results found for searched term "Mutant IDH1 inhibitor" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14456 | Mutant IDH1 inhibitor | Isocitrate Dehydrogenase (IDH) |
| Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM. | ||
| M6212 | BAY-1436032 | Isocitrate Dehydrogenase (IDH) |
| BAY1436032 | ||
| BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells. | ||
| M7368 | TC-E 5008 | Others |
| TC-E 5008 is a selective mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor; phenotypically lethal. | ||
| M9533 | DS-1001b (Safusidenib t-Butylamine) | Isocitrate Dehydrogenase (IDH) |
| Safusidenib | ||
| DS-1001b (Safusidenib t-Butylamine) is a potent, orally bioavailable, selective mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor with antitumor activity. | ||
| M10335 | IDH-305 | Isocitrate Dehydrogenase (IDH) |
| IDH305 | ||
| IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1(R132) mutation with IC50 values of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively. | ||
| M10434 | Olutasidenib (FT-2102) | Isocitrate Dehydrogenase (IDH) |
| FT-2102 | ||
| Olutasidenib (FT-2102) is a highly potent and selective, orally active, brain penetrant mutant Isocitrate dehydrogenase 1 (IDH1) inhibitor, with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively. | ||
| M14454 | Mutant IDH1-IN-1 | Isocitrate Dehydrogenase (IDH) |
| Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively. | ||
| M14455 | Mutant IDH1-IN-2 | Isocitrate Dehydrogenase (IDH) |
| Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay. | ||
| M28911 | GSK321 | Isocitrate Dehydrogenase (IDH) |
| GSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia. | ||
| M54535 | IDH1 Inhibitor 1 | Isocitrate Dehydrogenase (IDH) |
| IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-permeable, selective mutant IDH1 inhibitor that inhibits IDH1R132H, IDH1R132C, and IDH1WT with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM, respectively. possesses antitumor activity. | ||
| M54537 | Mutant IDH1-IN-4 | Isocitrate Dehydrogenase (IDH) |
| Mutant IDH1-IN-4 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH 1) with an IC50 value of ≤ 0.5 μM for mutant IDH 1 in R132H, HT1080 and U87R132H cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
